Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Celgene doubles down on Forma with a $600M discovery deal tied to a buyout option, signaling deep conviction in protein homeostasis as a next-wave oncology…
Celgene expands its pact with Forma, recognizing protein-homeostasis chemistry as a strategic complement to its IMiD franchise.
Celgene's Rupert Vessey on extending the pact: 'Our continued collaboration with FORMA is based upon the quality of their drug candidates, their adaptability…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Celgene paid Forma $225M upfront for a 3.5-year option-to-license arrangement on Forma's protein-homeostasis oncology pipeline. The deal was strategically notable as one of the largest preclinical option deals of 2014 and presaged the broader degrader/molecular-glue wave.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Celgene Corporation / Forma Therapeutics Holdings Inc. (this deal) | 2014 | $600M | — |
| Celgene Corporation / Bristol-Myers Squibb Company | 2015 | $2.0B | 85 |
| Celgene Corporation / Agios Pharmaceuticals Inc. | 2010 | $130M | 83 |
| Celgene Corporation / Bristol-Myers Squibb Company | 2018 | $9.0B | 68 |
| Celgene Corporation / Abraxis BioScience Inc. | 2010 | $2.9B | 65 |
| Celgene Corporation / Receptos Inc. | 2015 | $7.2B | 63 |
| Celgene Corporation / Impact Biomedicines | 2018 | $7.0B | 54 |
← Browse all deals · How we score deals
More: 2014 deals · Celgene Corporation deals · Hematology deals